Shamburg News · 8-K filed Oct 26, 2026, 5:09 PM EDT
Equillium Doses First Patient in EQ504 Trial, Triggers $20 Million Milestone Closing
EQ · Equillium, Inc.
- Financing
- Material agreement
- Reg FD disclosure
- Other event
- Materiality: high
Equillium announced on October 26, 2026 that it dosed the first subject in Australia in its Phase 1 trial of EQ504, which triggered the milestone closing of its August 2025 private placement. At the milestone closing, the Company issued 14,957,260 shares at $0.57 per share and 20,130,457 pre-funded warrants at $0.5669 per warrant, for aggregate gross proceeds of approximately $20.0 million. The Company expects its cash to fund planned operations into 2029.
Source: SEC EDGAR, Form 8-K, Items 3.02, 7.01, 8.01, 9.01, accession 0001193125-26-432158.
Written from the filing by Shamburg Markets. Figures are as reported by the company.